US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cybin Inc

11.73

-0.4500-3.69%

Volume:1.25M

Turnover:14.38M

Market Cap:857.00M

PE:-2.90

High:12.19

Open:11.98

Low:11.26

Close:12.18

52wk High:14.35

52wk Low:3.76

Shares:73.06M

Float Shares:59.74M

Volume Ratio:0.73

T/O Rate:2.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.0491

EPS(LYR):-3.8923

ROE:-86.94%

ROA:-44.38%

PB:3.54

PE(LYR):-3.01

Loading ...

Overview Company News Filings

Cybin (HELP) Shares Just Moved, So What Is Behind The Attention?

Simply Wall St.

Cybin (HELP) Is Up 19.8% After Deepening Psychedelic Pipeline And Leadership Shift Is The Risk Story Changing?

Simply Wall St.

OB Holdings Signs MoU with HELP University to Build Entrepreneurship Platform

MT Newswires Live

Cybin Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Helus Pharma Q1 EPS $(0.91) Beats $(1.07) Estimate

Benzinga Earnings

ASTROTECH APPOINTS STRATEGIC ADVISORY BOARD TO HELP ADVANCE LUNAR RESOURCES AND INFRASTRUCTURE INITIATIVE

Cybin Inc. Expected to Post a Loss of C$1.17 a Share - Earnings Preview

Helus Pharma Shares Rise After Appointing New CEO

MT Newswires Live

Helus Pharma appoints Michael Halstead as CEO

Helus Pharma Names Michael Halstead CEO

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR)

Helus Pharma Completes Enrollment in Phase 3 Study for Depression Treatment

MT Newswires Live

Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003

Chief Financial Officer Greg Cavers Sold A Bunch Of Shares In Cybin

Simply Wall St.

Helus Pharma price target lowered to $15 from $30 at Alliance Global

Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP) and Mettler-Toledo (MTD)

Cybin Inc Reports Results for the Quarter Ended March 31 - Earnings Summary

Helus Pharma Q4 EPS $(0.85) Beats $(1.11) Estimate

Benzinga Earnings

Calendar of U.S. Earnings Expected in the Week Ahead

Cybin (HELP) As Phase 3 Enrollment Progresses, The Undervalued Narrative Holds

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/HELP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HELP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELP\",,,,,undefined,":{"symbol":"HELP","market":"US","secType":"STK","nameCN":"Cybin Inc","latestPrice":11.73,"timestamp":1788205877276,"preClose":12.18,"halted":0,"volume":1248671,"delay":0,"changeRate":-0.036945812807881714,"floatShares":59740268,"shares":73060200,"eps":-4.049081,"marketStatus":"Trading","change":-0.45,"latestTime":"08-31 15:51:18 EDT","open":11.98,"high":12.1909,"low":11.255,"amount":14381327.248997001,"amplitude":0.076839,"askPrice":11.74,"askSize":200,"bidPrice":11.72,"bidSize":503,"shortable":3,"etf":0,"ttmEps":-4.049081,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788206400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":12.18,"preHourTrading":{"tag":"盘前","latestPrice":12.26,"preClose":12.18,"latestTime":"09:26 EDT","volume":2739,"amount":33425.4015645,"timestamp":1788182778716,"change":0.08,"changeRate":0.006568,"amplitude":0.036125},"postHourTrading":{"tag":"盘后","latestPrice":12.2,"preClose":12.18,"latestTime":"19:52 EDT","volume":10303,"amount":126828.4899,"timestamp":1787961136647,"change":0.02,"changeRate":0.001642,"amplitude":0.022989},"volumeRatio":0.728515,"impliedVol":1.2296,"impliedVolPercentile":0.4667},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELP\",,,,,undefined,":{"symbol":"HELP","floatShares":59740268,"roa":"-44.38%","roe":"-86.94%","lyrEps":-3.892309,"volumeRatio":0.728515,"shares":73060200,"dividePrice":0,"high":12.1909,"amplitude":0.076839,"preClose":12.18,"low":11.255,"week52Low":3.76,"pbRate":"3.54","week52High":14.35,"institutionHeld":0,"latestPrice":11.73,"committee":0.43101,"eps":-4.049081,"divideRate":0,"volume":1248671,"delay":0,"ttmEps":-4.049081,"open":11.98,"prevYearClose":8.18,"prevWeekClose":12.18,"prevMonthClose":7.82,"prevQuarterClose":6.61,"fiveDayClose":13.02,"twentyDayClose":8.06,"sixtyDayClose":4.43},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"HELP","fiscalQuarterEnding":"2026/06","expectedEps":-0.8,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-0.91},{"market":"US","date":"2026-06-29","symbol":"HELP","fiscalQuarterEnding":"2026/03","expectedEps":-1.04,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1782705600000,"reportTimeType":"pre","actualEps":-1.02},{"market":"US","date":"2026-02-13","symbol":"HELP","fiscalQuarterEnding":"2025/12","expectedEps":-0.53,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1770958800000,"reportTimeType":"pre","actualEps":-0.72}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":10,"updateTime":1785211200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HELP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HELP","date":"2026-08-28","current":-2.896954,"percent":0.012422,"low":-5.968006,"twenty":-4.154483,"median":-2.567348,"eighty":-1.928869,"high":-1.57152,"avg":-2.89102,"sd":1.060519,"marketCap":967316677},"quantilePoints":[{"date":"2026-01-09","current":-4.237274,"twenty":-4.344211,"median":-4.257397,"eighty":-4.216576,"marketCap":367789729},{"date":"2026-01-16","current":-4.513243,"twenty":-4.471847,"median":-4.329263,"eighty":-4.240723,"marketCap":391743470},{"date":"2026-01-23","current":-4.432752,"twenty":-4.4477,"median":-4.415504,"eighty":-4.256821,"marketCap":384756963},{"date":"2026-01-30","current":-3.892312,"twenty":-4.44425,"median":-4.332138,"eighty":-4.197028,"marketCap":337847553},{"date":"2026-02-06","current":-3.369121,"twenty":-4.439651,"median":-4.243023,"eighty":-3.91531,"marketCap":292435253},{"date":"2026-02-13","current":-3.403617,"twenty":-4.425853,"median":-4.199903,"eighty":-3.703734,"marketCap":295429471},{"date":"2026-02-20","current":-2.801935,"twenty":-4.400556,"median":-4.133785,"eighty":-3.477209,"marketCap":345246985},{"date":"2026-02-27","current":-3.151162,"twenty":-4.339612,"median":-3.892312,"eighty":-3.128422,"marketCap":388277769},{"date":"2026-03-06","current":-2.290278,"twenty":-4.333863,"median":-3.768701,"eighty":-3.012284,"marketCap":282201883},{"date":"2026-03-13","current":-2.083178,"twenty":-4.318914,"median":-3.656589,"eighty":-2.772698,"marketCap":256683628},{"date":"2026-03-20","current":-1.953233,"twenty":-4.27062,"median":-3.450978,"eighty":-2.359311,"marketCap":240672173},{"date":"2026-03-27","current":-1.888261,"twenty":-4.241873,"median":-3.369121,"eighty":-2.142465,"marketCap":232666446},{"date":"2026-04-02","current":-2.026327,"twenty":-4.237274,"median":-3.151162,"eighty":-1.973537,"marketCap":249678617},{"date":"2026-04-10","current":-2.127847,"twenty":-4.214276,"median":-3.041521,"eighty":-2.026327,"marketCap":262187565},{"date":"2026-04-17","current":-2.233427,"twenty":-4.185529,"median":-2.883151,"eighty":-2.079117,"marketCap":275196872},{"date":"2026-04-24","current":-2.334946,"twenty":-4.168281,"median":-2.755237,"eighty":-2.079117,"marketCap":287705821},{"date":"2026-05-01","current":-2.156272,"twenty":-4.099289,"median":-2.473013,"eighty":-2.079117,"marketCap":265690071},{"date":"2026-05-08","current":-2.168454,"twenty":-3.949806,"median":-2.332915,"eighty":-2.083178,"marketCap":267191145},{"date":"2026-05-15","current":-2.054753,"twenty":-3.892312,"median":-2.278095,"eighty":-2.070996,"marketCap":253181122},{"date":"2026-05-22","current":-1.867957,"twenty":-3.817571,"median":-2.245609,"eighty":-2.001963,"marketCap":230164657},{"date":"2026-05-29","current":-1.823288,"twenty":-3.808372,"median":-2.233427,"eighty":-1.952421,"marketCap":224660719},{"date":"2026-06-05","current":-1.798924,"twenty":-3.746279,"median":-2.217184,"eighty":-1.904504,"marketCap":221658571},{"date":"2026-06-12","current":-1.644614,"twenty":-3.694535,"median":-2.188759,"eighty":-1.887449,"marketCap":202644969},{"date":"2026-06-18","current":-1.859835,"twenty":-3.668088,"median":-2.162363,"eighty":-1.864708,"marketCap":229163941},{"date":"2026-06-26","current":-2.444587,"twenty":-3.642791,"median":-2.156272,"eighty":-1.87283,"marketCap":301215485},{"date":"2026-07-02","current":-2.630171,"twenty":-3.565692,"median":-2.168454,"eighty":-1.879327,"marketCap":389260009},{"date":"2026-07-10","current":-2.776757,"twenty":-3.45355,"median":-2.19891,"eighty":-1.885824,"marketCap":410954437},{"date":"2026-07-17","current":-2.948472,"twenty":-3.424315,"median":-2.233427,"eighty":-1.891509,"marketCap":436367909},{"date":"2026-07-24","current":-3.237455,"twenty":-3.399137,"median":-2.237487,"eighty":-1.896382,"marketCap":479136922},{"date":"2026-07-31","current":-3.40917,"twenty":-3.401377,"median":-2.263883,"eighty":-1.897194,"marketCap":504550394},{"date":"2026-08-07","current":-4.648869,"twenty":-3.432324,"median":-2.290278,"eighty":-1.901255,"marketCap":688023265},{"date":"2026-08-14","current":-4.795455,"twenty":-3.679587,"median":-2.339007,"eighty":-1.904504,"marketCap":709717693},{"date":"2026-08-21","current":-4.514739,"twenty":-3.872812,"median":-2.466832,"eighty":-1.909377,"marketCap":772941452},{"date":"2026-08-28","current":-5.650082,"twenty":-4.154483,"median":-2.567348,"eighty":-1.928869,"marketCap":967316677}],"updateTime":1788205878197},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663927960","title":"Cybin (HELP) Shares Just Moved, So What Is Behind The Attention?","url":"https://stock-news.laohu8.com/highlight/detail?id=2663927960","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663927960?lang=en_us&edition=fundamental","pubTime":"2026-08-28 23:29","pubTimestamp":1787930998,"startTime":"0","endTime":"0","summary":"Cybin (HELP) has moved into focus after advancing its lead psychedelic therapy HLP003 into a Phase 3 trial for major depressive disorder, alongside leadership changes including the appointment of Michael Halstead as CEO.\nCybin’s recent progress on HLP003 and leadership hires has come alongside sharp share price swings, with a 30 day share price return of 74.21% and a 90 day share price return of 190.99%. Over a 1 year period the total shareholder return is 73.30%, but the 5 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-shares-just-moved-so-what-is-behind-the-attention","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-shares-just-moved-so-what-is-behind-the-attention","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662744784","title":"Cybin (HELP) Is Up 19.8% After Deepening Psychedelic Pipeline And Leadership Shift Is The Risk Story Changing?","url":"https://stock-news.laohu8.com/highlight/detail?id=2662744784","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662744784?lang=en_us&edition=fundamental","pubTime":"2026-08-27 03:31","pubTimestamp":1787772662,"startTime":"0","endTime":"0","summary":"In August 2026, Cybin Inc. reported a first-quarter net loss of US$47.82 million, with basic and diluted loss per share from continuing operations of US$0.91, while Helus Pharma appointed experienced HR leader Regina Donohue as Chief People Officer and CNS drug-development expert Suresh Durgam, M.D., to its Scientific Advisory Board.\nInvestor interest in Cybin has been influenced by its psychedelic medicine pipeline progress, including HLP003 entering a Phase 3 trial for major depressive...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-is-up-198-after-deepening-psychedelic-pipeline-an","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-is-up-198-after-deepening-psychedelic-pipeline-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QTOC","CHAT","ARTY","HELP","BK4007","AGIX","VTHR","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660110264","title":"OB Holdings Signs MoU with HELP University to Build Entrepreneurship Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2660110264","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660110264?lang=en_us&edition=fundamental","pubTime":"2026-08-19 12:36","pubTimestamp":1787114175,"startTime":"0","endTime":"0","summary":"OB Holdings  signed a memorandum of understanding with HELP University to jointly develop an AI entrepreneurship platform and create similar opportunities, according to a Tuesday filing with Bursa Malaysia.The fortified food and dietary supplements maker aims to speed up the commercialization of AI innovations, build talent and practical skills and improve employability through the partnership.In the second phase of the partnership, the company may host student internships at its high-tech manufacturing facility.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELP","BK4007","BGSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659441831","title":"Cybin Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659441831","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659441831?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:15","pubTimestamp":1786713350,"startTime":"0","endTime":"0","summary":"Cybin Inc. reports results for the quarter ended June 30 - Earnings SummaryCybin Inc.HELP.NLBreported a quarterly adjusted loss of C$1.26 per share for the quarter ended June 30, higher than the same ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B0VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659146118","title":"Helus Pharma Q1 EPS $(0.91) Beats $(1.07) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659146118","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659146118?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:53","pubTimestamp":1786708407,"startTime":"0","endTime":"0","summary":"Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(1.07) by 14.95 percent. This is a 17.27 percent increase over losses of $(1.10) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61205038/helus-pharma-q1-eps-0-91-beats-1-07-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908918","title":"ASTROTECH APPOINTS STRATEGIC ADVISORY BOARD TO HELP ADVANCE LUNAR RESOURCES AND INFRASTRUCTURE INITIATIVE","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908918","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908918?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:15","pubTimestamp":1786540500,"startTime":"0","endTime":"0","summary":"Advisors will support Astrotech's planned proposal under NASA's upcoming final NextSTEP-3 Appendix A solicitation and bring experience in space systems, lunar science, autonomous mining, artificial in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343754/0/en/astrotech-appoints-strategic-advisory-board-to-help-advance-lunar-resources-and-infrastructure-initiative.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","ARKX","HELP","XT","BK4564","BK4544","UFO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657610463","title":"Cybin Inc. Expected to Post a Loss of C$1.17 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657610463","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657610463?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:14","pubTimestamp":1786101247,"startTime":"0","endTime":"0","summary":"Cybin Inc. <HELP.NLB> expected to post a loss of C$1.17 a share - Earnings PreviewCybin Inc.HELP.NLBis expected to  show no change in quarterly revenue when it reports  results on August 11 (estimated","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4440Z2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657255025","title":"Helus Pharma Shares Rise After Appointing New CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2657255025","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657255025?lang=en_us&edition=fundamental","pubTime":"2026-08-05 22:54","pubTimestamp":1785941658,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) shares rose 5% on Wednesday after the company said it appointed Michael Halstead as chief executive officer, effective immediately.Halstead was most recently the president of Intra","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657152341","title":"Helus Pharma appoints Michael Halstead as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2657152341","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657152341?lang=en_us&edition=fundamental","pubTime":"2026-08-05 22:38","pubTimestamp":1785940721,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) announced Monday the appointment of Michael Halstead as CEO. Halstead brings 25 years of industry experience, most recently ser...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-pharma-appoints-michael-halstead-as-ceo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-pharma-appoints-michael-halstead-as-ceo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656371843","title":"Helus Pharma Names Michael Halstead CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2656371843","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656371843?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:45","pubTimestamp":1785761102,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) appointed Michael Halstead as chief executive officer, effective immediately, the company said Monday.Halstead previously served as president of Intra-Cellular Therapies, the company said.Shares of the company were up 2.2% in Monday premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653719909","title":"Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653719909","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653719909?lang=en_us&edition=fundamental","pubTime":"2026-07-23 13:50","pubTimestamp":1784785838,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nek...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-johnson-johnson-jnj-helus-pharma-help-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-johnson-johnson-jnj-helus-pharma-help-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGXZ57979304.SGD","IE000BZT7R73.USD","LU1674673691.USD","JNJ","TRUH","LU0210536198.USD","IE00B3PB1722.GBP","IE000MB6IJN5.SGD","LU0053666078.USD","LU1244550221.USD","LU0689626769.HKD","JDOC","HCSG","BK4532","IHE","LU1074936037.SGD","HELP","LU2602419157.SGD","XBI","VHT","IE00BGHQF631.EUR","NKTR","LU0787776722.HKD","PJP","LU1629891620.HKD","LU0683600562.USD","IXJ","LABU","IE00BSNM7G36.USD","FHLC","LU1032955483.USD","BMED","GDOC","IE00B4R5TH58.HKD","FTXH","IE00B42XCP33.USD","LU0882574055.USD","XLV","LU0162691827.USD","LU1196500208.SGD","LU0124676726.USD","LU0820561909.HKD","RXL","LU0029874061.USD","IYH","MEDX","LU0234572021.USD","LU0345769631.USD","LU1162221912.USD","LU1718418525.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653016762","title":"Helus Pharma Completes Enrollment in Phase 3 Study for Depression Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2653016762","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653016762?lang=en_us&edition=fundamental","pubTime":"2026-07-22 00:06","pubTimestamp":1784649966,"startTime":"0","endTime":"0","summary":"Helus Pharma  said Tuesday it has completed enrollment in its phase 3 study of HLP003 in patients living with major depressive disorder.The trial enrolled 223 adults with moderate to severe major depressive disorder who experience an inadequate response despite a stable antidepressant regimen, the company said.The pharmaceutical company expects to release topline data in Q4 and targets a potential new drug application with the US Food and Drug Administration in 2028, it added.Enrollment is continuing in the program's second pivotal study, and eligible participants can roll over into a long-term extension trial to further evaluate safety, Helus Pharma said.Shares of the company were up nearly 16% in Tuesday trading.Price: 8.33, Change: +1.22, Percent Change: +17.16","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653060422","title":"Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003","url":"https://stock-news.laohu8.com/highlight/detail?id=2653060422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653060422?lang=en_us&edition=fundamental","pubTime":"2026-07-21 23:05","pubTimestamp":1784646331,"startTime":"0","endTime":"0","summary":"Helus Pharma (HELP) has completed enrollment in its APPROACH Phase 3 pivotal study of HLP003 in patients living with Major Depressive Disorder. APP...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-pharma-completes-enrollment-in-phase-3-approach-study-of-hlp003-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-pharma-completes-enrollment-in-phase-3-approach-study-of-hlp003-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652218051","title":"Chief Financial Officer Greg Cavers Sold A Bunch Of Shares In Cybin","url":"https://stock-news.laohu8.com/highlight/detail?id=2652218051","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652218051?lang=en_us&edition=fundamental","pubTime":"2026-07-20 18:17","pubTimestamp":1784542665,"startTime":"0","endTime":"0","summary":"We'd be surprised if Cybin Inc. ( NASDAQ:HELP ) shareholders haven't noticed that the Chief Financial Officer, Greg...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/chief-financial-officer-greg-cavers-sold-a-bunch-of-shares-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/chief-financial-officer-greg-cavers-sold-a-bunch-of-shares-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651109798","title":"Helus Pharma price target lowered to $15 from $30 at Alliance Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2651109798","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651109798?lang=en_us&edition=fundamental","pubTime":"2026-07-14 21:41","pubTimestamp":1784036468,"startTime":"0","endTime":"0","summary":"Alliance Global lowered the firm’s price target on Helus Pharma (HELP) to $15 from $30 and keeps a Buy rating on the shares, based on a sum-of-the-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/helus-pharma-price-target-lowered-to-15-from-30-at-alliance-global-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/helus-pharma-price-target-lowered-to-15-from-30-at-alliance-global-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650237379","title":"Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP) and Mettler-Toledo (MTD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650237379","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650237379?lang=en_us&edition=fundamental","pubTime":"2026-07-09 18:20","pubTimestamp":1783592423,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Helus Pharma (HELP) and Mettler-Toledo (MTD) with bu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-helus-pharma-help-and-mettler-toledo-mtd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-helus-pharma-help-and-mettler-toledo-mtd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2413666426.HKD","HELP","LU1721428933.USD","LU1093756168.USD","BK4588","LU2413666699.HKD","BK4007","LU0029874061.USD","XLV","BK4121","BK4137","LU2211817866.USD","BK4533","BK4581","LU1093756325.SGD","BK4548","LU0128526141.USD","BK4585","LU0347712357.USD","MTD","IE00BFXG0V08.USD","XBI","IE00B5TLWC47.USD","IE00BYQQ9H92.USD","BK4567","LABU","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647302057","title":"Cybin Inc Reports Results for the Quarter Ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2647302057","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647302057?lang=en_us&edition=fundamental","pubTime":"2026-06-30 05:03","pubTimestamp":1782766994,"startTime":"0","endTime":"0","summary":"Cybin Inc reports results for the quarter ended March 31 - Earnings SummaryCybin IncHELP.NLBreported a quarterly adjusted loss of C$1.17 per share for the quarter ended March 31, higher than the same ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nL8N4311WE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647743963","title":"Helus Pharma Q4 EPS $(0.85) Beats $(1.11) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2647743963","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647743963?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:46","pubTimestamp":1782737209,"startTime":"0","endTime":"0","summary":"Helus Pharma (NASDAQ:HELP) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.11) by 23.42 percent. This is a 16.67 percent increase over losses of $(1.02) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/06/60154129/helus-pharma-q4-eps-0-85-beats-1-11-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647378925","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2647378925","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647378925?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:00","pubTimestamp":1782727200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. Constellation Brands Inc. Class A                1Q      3.20       AMC. NIKE Inc. Class B                                4Q       .12   4:15 PM. FactSet Research Syss Inc.                       3Q      4.45   6:00 AM. MSC Indus Direct Co. Inc. Class A                3Q      1.27   6:30 AM. Lindsay Corp.                                    3Q      1.14   6:45 AM Dow Jones NewswiresJune 29, 2026 06:00 ET Copyright  2026 Dow Jones & Company, Inc.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKE","BK4532","BK4547","LU2552382058.USD","AVXX","AVAV","AMC","LU2552382132.HKD","LU0310800379.SGD","LU2095319765.USD","FDS","STZ","BK4112","BK4504","BK4581","CNXC","BK4534","LU0823411888.USD","LU0792757196.USD","LU2210149790.SGD","BK4152","LU2098885051.SGD","LU2065170008.USD","LU2065169927.USD","BK4007","LU2552382215.SGD","LNN","LU1267930813.SGD","MSM","LU2065732104.USD","GIS","PRGS","LU0889566641.SGD","IE00BYQQ9H92.USD","BK4106","UNF","LU0052756011.USD","LU0029864427.USD","FC","LU1585245621.USD","BK4123","BK4149","LU0786609619.USD","LU1267930227.SGD","BK4104","BK4226","LU1267930573.SGD","LU1303367103.USD","GBX","HELP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647343036","title":"Cybin (HELP) As Phase 3 Enrollment Progresses, The Undervalued Narrative Holds","url":"https://stock-news.laohu8.com/highlight/detail?id=2647343036","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647343036?lang=en_us&edition=fundamental","pubTime":"2026-06-29 03:08","pubTimestamp":1782673723,"startTime":"0","endTime":"0","summary":"Cybin (HELP) is drawing fresh attention after reporting that enrollment in its APPROACH Phase 3 trial for HLP003 in major depressive disorder has surpassed 86%, a key marker in its broader PARADIGM program.\nSee our latest analysis for Cybin.\nThe recent APPROACH trial update comes after a sharp short term rebound in Cybin's 1 week and 1 month share price returns of 38.76% and 42.42% respectively. This is set against a year to date share price return that is still down 21.74% and a 5 year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-as-phase-3-enrollment-progresses-the-undervalued","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-help/cybin/news/cybin-help-as-phase-3-enrollment-progresses-the-undervalued","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","HELP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}]}}